FUJIFILM Holdings Corporation (FUJIY)

Other OTC - Other OTC Delayed Price. Currency in USD

Add to watchlist

80.63

+1.77

(+2.24%)

As of 10:28AM EST. Market open.

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	78.86
Open	80.63
Bid	0.00 x 0
Ask	0.00 x 0
Day's Range	80.49 - 80.71
52 Week Range	50.08 - 91.87
Volume	4,545
Avg. Volume	23,937

Market Cap	32.344B
Beta (5Y Monthly)	0.15
PE Ratio (TTM)	17.55
EPS (TTM)	4.59
Earnings Date	N/A
Forward Dividend & Yield	0.95 (1.19%)
Ex-Dividend Date	Mar 29, 2021
1y Target Est	97.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for FUJIY

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

FUJIFILM HOLDINGS CORPORATION
Technical Assessment: Bullish in the Intermediate-TermWe noted last week that long-term measures of market breadth remain supportive of higher stock prices, while intermediate-term breadth has improved and is neutral/mildly bullish. And then along came the new coronavirus variant to knock the market off its pins.
Rating
Fair Value
Economic Moat
2 days agoArgus Research

All

News

Press Releases

Research Reports

Zacks
Why FUJIFILM (FUJIY) Might Surprise This Earnings Season
FUJIFILM (FUJIY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
MarketWatch
The success of Merck’s antiviral — and other COVID-19 pills in development — may depend on how quickly people start taking them
In the not-too-distant future, you may be able to walk into a doctor’s office, get tested for SARS-CoV-2, and walk out with pills or a prescription if you end up testing positive for the virus. “Finally, we have another potential tool,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to President Joe Biden, said Oct. 6 at a White House briefing, “a promising new oral drug that people could take at home soon after COVID-19 to reduce the risk of severe outcomes.” The drug is molnupiravir, which Merck & Co. Inc. (MRK) and Ridgeback Therapeutics say cuts the risk of hospitalization and death by 50%.
Reuters
Japanese shares drop on economic worries, stronger yen
Japanese shares fell on Monday as concerns of slow economic growth due to the highly contagious Delta variant of COVID-19 weighed on investor sentiment, while market heavyweights Toyota Motor and Sony Group dropped due to a stronger yen. "And the worse-than-expected outcome of the University of Michigan's consumer survey indicated an impact of the Delta variant in the U.S. and that weakened the dollar." The survey released last week showed consumer sentiment slid to the lowest level since 2011 amid an acceleration in COVID-19 infections caused by the Delta variant.